Back to Agenda
Session 9: Engaging the Customer - Health Care Providers
Session Chair(s)
Michael Richardson, MD, FFPM, FRCP
Senior Vice President, WorldWide Patient Safety
Bristol-Myers Squibb, United Kingdom
New data sources and methodologies are improving our ability to assess risk and risk-benefit balance associated with medical product use, but this information must be appropriately shared to facilitate decision making by all stakeholders, including health care providers and especially patients. How are risk and risk mitigation approaches most effectively shared with health care providers, and how can effective feedback on adverse events be best communicated to sponsors? What approaches to sharing benefit-risk information are most meaningful and useful to the patient in his or her decision making? What tools does FDA use to communicate with the public about drug safety and risks, and what impact have these messages had on health care professional and patient or consumer decision making? In this session, patient representatives and communication professionals from industry and FDA will explore how well current methods are working and how they can be improved.
Speaker(s)
Effective Risk Management Communications with Health Care Providers
Reema Mehta, PharmD, MPH
Pfizer Inc, United States
Senior Director, Head of Risk Management and Safety Surveillance Research
Patient Perspectives on Risk Benefit and Risk Management Messages
James A. Seaton
Seaton Associates, LLC, United States
Executive Consultant
FDA Risk Communications to the Public: Impact and Outcomes
Paula Rausch, PhD, RN
FDA, United States
Director, Division of Health Communications, Office of Communications, CDER
Evaluating Drug Safety Communication: Research Gaps and Opportunities
Sally Okun, BSN, MHS, MBA, RN
Clinical Trials Transformation Initiative (CTTI), United States
Executive Director
Have an account?